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OBJECTIVES: The phosphatidylinositol 3-kinase/AKT axis is an important cell-signaling pathway that mediates cell
proliferation and survival, two biological processes that regulate malignant cell growth. The phosphatidylinositol 3-
kinase CA gene encodes the p110a subunit of the phosphatidylinositol 3-kinase protein. There are phosphatidy-
linositol 3-kinase CAmutations in several types of human tumors, and they are frequently observed in breast cancer.
However, these mutations have not been investigated in Brazilian breast cancer patients.
METHODS: PCR-SSCP and direct DNA sequencing were performed to identify phosphatidylinositol 3-kinaseCA exon
9 and exon 20 mutations in 86 patients with sporadic breast cancer. The relationships between PIK3CA mutations
and patient clinicopathological characteristics and survival were analyzed. The presence of the TP53 mutation was
also examined.
RESULTS: Twenty-three (27%) of the 86 primary breast tumors contained PIK3CA mutations. In exons 9 and 20, we
identified the hotspot mutations E542K, E545K, and H1047R, and we identified two new missense mutations
(I1022V and L1028S) and one nonsense (R992X) mutation. Phosphatidylinositol 3-kinase CA exon 20 mutations were
associated with poor overall survival and TP53 gene mutations.
CONCLUSIONS: Phosphatidylinositol 3-kinase CA mutations are common in tumors in Brazilian breast cancer
patients, and phosphatidylinositol 3-kinase CA and TP53 mutations are not mutually exclusive. Phosphatidylinositol
3-kinase CA exon 20 mutations are associated with poor survival, and they may be useful biomarkers for identifying
breast cancer patients with aggressive tumors and for predicting the response to treatment with PI3K pathway
inhibitors.
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INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K)/AKT signaling
pathway plays an important role in cellular processes, such
as proliferation, differentiation, survival, and migration
(1,2). Alterations in the components of this signaling
pathway, including gain-of-function mutations in the p110
catalytic subunit of PI3K, have been identified in a wide
spectrum of human cancers (3,4). Class I PI3Ks are
heterodimers composed of catalytic (p110) and regulatory
(p85) subunits involved in regulating cell division and in
tumorigenesis (5,6).
The PIK3CA gene comprises 20 exons encoding the p110a
catalytic subunit. This gene is mutated in a wide range of
tumors, including glioblastomas, gastric cancers, lung
cancers, ovarian cancers, hepatocellular carcinomas, endo-
metrial carcinomas, brain cancers, and breast cancers (3).
The majority of PIK3CA mutations cluster in hotspot regions
in exon 9 (the helical domain) and exon 20 (the kinase
domain). The most common missense mutations change
amino acid residues E542 and E545 to lysine in the helical
domain and change H1047 to arginine in the kinase domain.
Functional studies suggest that these particular PIK3CA
mutations lead to increased PI3K activity (6,7).
The frequency of PIK3CA mutations in breast cancer
ranges from 16.4 to 45% (3,8-10). However, the association
between PIK3CA mutations and specific clinicopathologi-
cal features of breast cancer is still a matter of debate.
Furthermore, the relationship between the presence of
PIK3CA mutations in breast cancer patients and overall
survival (OS) and disease-free survival (DFS) is controver-
sial. Some studies have found that breast cancer patients
with PIK3CA gene mutations have improved OS and DFS
rates compared with breast cancer patients lacking such
mutations (9,11-13). Conversely, other studies have found
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that the presence of PIK3CA mutations is correlated with
poor outcome (14-16).
In the present study, we identified mutations in exons 9
and 20 of the PIK3CA gene in primary breast tumors from
Brazilian breast cancer patients, and we analyzed the
relationship between mutational status and patient clinico-
pathological features and outcomes.
MATERIALS AND METHODS
Tumor samples and genomic DNA extraction
Samples from 86 primary breast tumors were obtained
from breast cancer patients diagnosed at the Hospital do
Cancer A. C. Camargo, Sa˜o Paulo, Brazil, from February 1993
to March 1998. The median follow-up time was 63.3 months
(range, 25 to 78 months). None of the patients had received
any medical treatment related to their breast cancer before
the biopsy/mastectomy procedure. After surgical excision,
biopsy specimens were immediately frozen and stored in
liquid nitrogen until DNA extraction. Histopathological
review of the tumor slides was performed to confirm the
diagnosis. All tumors were classified according to the World
Health Organization Histological Typing of Breast Tumors
classification, and the clinical stage of each patient was
determined according to the 5th Edition of the UICC TNM
classification of malignant tumors. The tumors were all
infiltrating ductal carcinomas. The median age of the patients
at the time of diagnosis was 55 years (range, 26 to 85 years).
The patient and tumor characteristics are shown in Table 1.
Tissue specimens were ground to a powder under liquid
nitrogen using a Frozen Tissue Pulverizer (Termovac
Industries, Copiague, N.Y.), and high-molecular-weight
DNA was extracted as previously described (17). This study
was approved by the Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo Ethics Committee.
All subjects were given information about the study and
provided written informed consent.
Mutation analysis by polymerase chain reaction-
single stranded conformation polymorphism (PCR-
SSCP) and direct DNA sequencing
Two sets of primers were used to amplify exon 9 (forward:
59-CCAGAGGGGAAAAATATGACA-39; reverse: 59-CAT-
TTTAGCACTTACCTGTGAC-39) and exon 20 (forward: 59-
CATTTGCTCCAAACTGACCA-39; reverse: 59-TGAGCT-
TTCATTTTCTCAGTTATCTTTTC-39) of the PIK3CA gene.
The PCR products were separated using the GeneGelTM
Excel 12.5/24 Kit (GE Healthcare, Sweden) according to
the manufacturer’s instructions. Gels were stained using the
DNA Silver Staining Kit (GE Healthcare) according to the
manufacturer’s instructions. Samples exhibiting differences
in gel band mobility were cloned (TOPO-TA CloningH Kit,
Invitrogen) and then sequenced using a MegaBACE 1000
automatic sequencer (Amersham Biosciences) and the ET
Dye Terminator Kit (Amersham Biosciences). All sequences
were analyzed using Mutation Surveyor software v3.2
(SoftGenetics).
Statistical analysis
Fisher’s exact test and Spearman’s rho correlation were
used to assess the association and the direction of the
association, respectively, among categorical variables. OS
and DFS rates were calculated based on the Kaplan-Meier
method, and the curves were compared using the log-rank
test. OS and DFS rates were determined from the day of the
diagnosis to the date of death or to the date on which
recurrence was detected, respectively.
Statistical analyses were performed using IBM SPSS
Statistics 19.0, 2010 (SPSS Chicago, IL). Differences were
considered significant when the p-value was less than 0.05.
RESULTS
We investigated mutations in exon 9 and exon 20 of the
PIK3CA gene in 86 primary breast tumors by performing
SSCP analysis and DNA sequencing. Of the 86 tumors, 23
(27%) exhibited PIK3CA mutations: 13% in exon 9 and 14%
in exon 20. Table 2 lists the PIK3CA variants identified by
DNA sequencing. We characterized seven non-synonymous
variants, two of which were new (I1022V, L1028S); three
synonymous variants, two of which were new (S541S,
L1028L); one new stop codon-gain variant (R992X); and
one previously known stop codon-loss (X1069W) variant.
Figure 1 shows representative electropherograms of the
PIK3CA variants characterized in the primary breast tumors.
Table 1 - Patient and tumor characteristics (n = 86).
Variable Characteristic n (%)
Age, y #55 45 (52.3)
.55 41 (47.7)
Stage, TNM Early 37 (43.0)
Late 49 (57.0)
Tumor size, ,4.0 44 (51.2)
cm $4.0 42 (48.8)
Lymph node Negative 22 (25.6)
Metastasis Positive 64 (74.4)
Hormonal Pre-menopause 30 (34.9)
status Post-menopause 56 (65.1)
ER Negative 27 (31.4)
Positive 53 (61.6)
Missing 06 (7.0)
PR Negative 43 (50.0)
Positive 37 (43.0)
Missing 06 (7.0)
HER2 Negative 71 (82.6)
Positive 08 (9.3)
Missing 07 (8.1)
TP53Mut No 63 (73.3)
Yes 10 (11.6)
Missing 13 (15.1)
TNM: tumor, nodes, and metastases; ER: estrogen receptor;
PR: progesterone receptor; HER2: human epidermal growth factor
receptor 2.
Table 2 - Observed variations in PIK3CA mutations in
exons 9 and 20 in breast tumors (n= 86).
Nucleotide Variation ID Residue Variation type
70282G.A COSM763 E545K Non-synonymous coding
70223A.G COSM41783 E525G Non-synonymous coding
70273G.A COSM760 E542K Non-synonymous coding
70272T.G - S541S Synonymous coding
86110C.T - R992X Stop codon gained
86171A.G COSM27130 E1012G Non-synonymous coding
86200A.G - I1022V Non-synonymous coding
86211C.T rs17849079 T1025T Synonymous coding
86218T.C - L1028L Synonymous coding
86219T.C - L1028S Non-synonymous coding
86276A.G COSM775 H1047R Non-synonymous coding
86343A.G COSM17449 X1069W Stop codon lost
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New variants were considered mutations, as they were not
present in the paired normal tissue of the same patients
(data not shown). The frequency of the hotspot mutation
E545K was 8.1%, corresponding to 63.6% of the helical (exon
9) mutations. The other common helical (exon 9) mutation,
E542K, was observed in only one case. The kinase (exon 20)
hotspot mutation H1047R was observed at a frequency of
14%, representing 91.7% of the PIK3CA exon 20 mutations.
Next, we investigated whether PIK3CA mutations were
associated with breast cancer development and progression.
The demographic and clinicopathological characteristics of
patients with tumors containing PIK3CA mutations were
compared with those of patients with tumors lacking
PIK3CA mutations. There were no statistically significant
differences between the clinicopathological features or
steroid hormone receptor status in patients with or without
PIK3CA mutations (Table 3).
Using a data set of TP53 mutations published previously
by our group (17), we evaluated whether any of the 73
patients had both PIK3CA and TP53 mutations. None of
the tumors with exon 9 PIK3CA mutations (PIK9mut) also
contained TP53 mutations. In contrast, we observed a
correlation between the presence of exon 20 PIK3CAmutations
(PIK20mut) and TP53 mutations (Fisher’s test p-value = 0.05,
Spearman’s correlation = 0.03, r = 0.253; Table 3).
We also tested whether PIK3CA mutations were asso-
ciated with patient OS or DFS. A comparison of patients
who had tumors with or without PIK3CA mutations
revealed no significant differences in cancer-specific survi-
val. On the other hand, when patients were grouped
according to the presence of PIK3CA helical domain (exon
9) or kinase domain (exon 20) mutations, the presence of
exon 20 mutations was associated with poorer OS (p= 0.026)
and DFS (p= 0.079) (Table 4 and Figure 2). We further
analyzed the relationship between survival and exon 20
mutations by conducting Kaplan-Meier analyses. We found
that patients with tumors harboring exon 20 mutations had
a significantly shorter mean OS and DFS compared with
patients lacking exon 20 mutations (median OS: 24.1 months
and not reached, respectively, p= 0.007; median DFS: 15.9
months and not reached, respectively, p= 0.025) (Table 4
and Figure 2).
DISCUSSION
No previous study has investigated the frequency and
spectrum of PIK3CA mutations in primary tumors from
Figure 1 - Representative eletropherograms of the PIK3CAmutations characterized in the breast cancer biopsy samples in this study. (A)
Known mutations and (B) new mutations.
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Brazilian breast cancer patients. In this study, we identified
PIK3CA mutations in primary breast tumors from a group of
Brazilian breast cancer patients and correlated these muta-
tions with patient clinicopathological features and out-
comes. The observed frequency of PIK3CA mutations was
27%, which is in accordance with similar studies that have
examined the frequency of exon 9 and 20 mutations
(frequency range, 16.4 to 45%) (3,8-10). This result indicates
that PIK3CA mutations are quite common genetic events in
tumors in Brazilian breast cancer patients. The frequency of
the most common missense activating mutations (E542K,
E545K, and H1047R) in the primary breast tumors was
82.6%, the same rate previously reported in the literature
(11). We also identified three new PIK3CA variants, two
missense variants, and one nonsense variant. These variants
were considered mutations, as they were not present in the
paired normal tissue of the same patients (data not shown).
In our analysis of the relationship between PIK3CA
mutations and patient clinicopathological characteristics,
we found no significant correlations between PIK3CA
mutations and patient age, clinical stage, tumor size, or
lymph node metastasis. Some previous studies showed
significant associations between PIK3CA mutations and
steroid hormone (estrogen and/or progesterone) receptor
status in breast cancer patients (13,14,18,19), while others
failed to find such associations (12,15). Although the
association between PIK3CA mutations and steroid hor-
mone receptor status did not reach statistical significance,
we observed a higher frequency of PIK3CA mutations in
estrogen receptor-positive tumors compared with receptor–
negative tumors, mainly in exon 9.
The association between PIK3CA mutations and breast
cancer patient survival remains controversial. In the present
work, we found that kinase domain (exon 20) mutations
were strongly associated with poorer OS and DFS. Various
studies have reported that the presence of PIK3CA muta-
tions is associated with good prognosis (11,13), is associated
with poor prognosis (14,16), or has no survival effect (18,20)
in breast cancer patients. Kalinsky et al. (13) found a direct
association between the presence of mutations in the C2,
helical, or kinase functional domains and better DFS or OS.
They also found that the H1047R mutation was strongly
associated with the absence of lymph node metastasis (13).
Similarly, Maruyama et al. (11) described a positive








n No Yes No Yes No Yes
Age, y ,55 45 34 11 0.63 40 5 0.75 39 6 1.00
$55 41 29 12 35 6 35 6
Stage, Early 37 28 9 0.81 31 6 0.52 34 3 0.22
TNM Late 49 35 14 44 5 40 9
Tumor size, ,4.0 39 31 8 0.33 34 5 1.00 36 3 0.21
Cm $4.0 47 32 15 41 6 38 9
Lymph node Negative 22 17 5 0.78 18 4 0.46 21 1 0.28
metastasis Positive 64 46 18 57 7 53 11
Hormonal status Pre-menopause 30 25 5 0.13 28 2 0.31 28 2 0.53
Post-menopause 56 38 18 47 9 47 9
ER Negative 27 22 5 0.19 26 1 0.09 23 4 1.00
Positive 53 35 18 43 10 45 8
PR Negative 43 33 10 0.45 39 4 0.33 37 6 1.00
Positive 37 25 12 30 7 32 5
HER2 Negative 71 54 17 0.20 63 8 1.00 62 9 0.10
Positive 8 4 4 7 1 5 3
TP53mut No 63 44 19 0.71 52 11 0.34 55 8 0.05
Yes 10 6 4 10 0 6 4
*Fisher’s exact test.
Table 4 - Association between PIK3CA mutations and patient survival.
Category n
Survival






PIKmut No 50 70.0 NR 0.163 NR 0.257
Yes 22 54.5 NR NR
PIKmut No 50 70.0 NR 0.026 NR 0.079
PIK9 10 70.0 NR NR
PIK20 12 41.7 24.1 15.9
PIK9mut No 62 64.5 NR 0.548 NR 0.531
Yes 10 70.0 NR NR
PIK20mut No 60 70.0 NR 0.007 NR 0.025
Yes 12 41.7 24.1 15.9
Median survival reported in months; NR: not reached.
PIK3CA mutations in breast cancer patients
Mangone FR et al.
CLINICS 2012;67(11):1285-1290
1288
correlation between the presence of mutations in any
domain of the PIK3CA gene and better relapse-free survival.
Taken together, these studies suggest a protective role for
these mutations. On the other hand, similar to our study,
two other studies reported that exon 20 mutations were
associated with poorer OS (14,16). It is difficult to compare
these studies because of the studies’ population hetero-
geneity and because there may have been differences in the
therapeutic strategies not mentioned in the publications.
Mutations in TP53 and PIK3CA are frequent in breast
cancer (21). In the present study, we found a positive
correlation between the presence of PIK3CA exon 20 and
Figure 2 - Kaplan-Meier curves showing long-term survival in primary breast cancer patients, stratified according to PIK3CA mutation
status. (A) Overall survival and (B) disease-free survival curves were calculated for the stratified patient groups. ‘No’ indicates patients
with tumors with no PIK3CA mutations; ‘PIK9’ indicates patients with tumors with PIK3CA mutations in exon 9; and ‘PIK20’ indicates
patients with tumors with PIK3CAmutations in exon 20. (C) Overall survival and (D) disease-free survival curves were calculated for the
stratified patient groups. ‘No’ indicates patients with tumors with no PIK3CA mutations in exon 20, and ‘Yes’ indicates patients with
tumors with PIK3CA mutations in exon 20. p-values were calculated using the log-rank test.
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TP53 mutations, with four samples exhibiting mutations in
both genes. This result suggests that the presence of these
mutations is not mutually exclusive, as was proposed by
Boyault et al. (19). We previously reported that patients with
tumors harboring TP53 mutations affecting amino acids
involved directly in DNA or zinc binding had a poor
prognosis (17). Interestingly, in this study, we found that the
presence of PIK3CA exon 20 mutations could be used to
stratify patients into distinct prognostic groups, regardless
of whether a TP53 mutation was present.
In summary, this is the first study to report that PIK3CA
mutations are common in tumors in Brazilian breast cancer
patients. We found that PIK3CA exon 20 mutations were
significantly associated with TP53 mutations, indicating that
PIK3CA mutations and TP53 mutations are not mutually
exclusive. Our finding that PIK3CA exon 20 mutations were
associated with more aggressive breast cancer and poor
outcomes, regardless of the treatment regimen, has impor-
tant clinical implications.
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